not Microsatellite Instability-High (not MSI-H)
1 drugsPredictive biomarker for patient selection in 5 indications
1
Approved Drugs
5
Indications
1
Companies
not Microsatellite Instability-High (not MSI-H) is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, Advanced renal cell carcinoma (first-line, in combination with pembrolizumab), Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus). Explore the targeted therapies, indications, testing methods, and companies developing not Microsatellite Instability-High (not MSI-H) drugs below.
Search not Microsatellite Instability-High (not MSI-H) Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting not Microsatellite Instability-High (not MSI-H)
| Drug | Company | Therapeutic Area |
|---|---|---|
| LENVIMA | EISAI INC | Oncology |
not Microsatellite Instability-High (not MSI-H) Indications
Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Advanced renal cell carcinoma (first-line, in combination with pembrolizumab) Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus) Unresectable hepatocellular carcinoma (first-line) Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab)